• Users Online: 1158
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2015  |  Volume : 40  |  Issue : 4  |  Page : 201-202

Rituximab-containing chemotherapy in pregnancy with malignancy

1 Department of Hematology, NRS Medical College and Hospital, Kolkata, West Bengal, India
2 Department of Gynaecology, Midnapore Medical College, Midnapore, West Bengal, India

Correspondence Address:
Tuphan K Dolai
Department of Hematology, NRS Medical College and Hospital, 138, AJC Bose Road, Kolkata 700014, West Bengal
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1110-1067.170222

Rights and Permissions

Non-Hodgkin lymphoma diagnosed during pregnancy often has an aggressive histology, with diffuse large B-cell or peripheral T-cell lymphomas being most common in this context. Aggressive lymphomas during pregnancy present a difficult challenge in diagnosis, especially in staging by means of radiological evaluation. The aim of the treatment is to give the mother the best chance for cure but at the same time with minimal harm to the fetus. Most cytotoxic agents, including rituximab, cross the human placenta and reach the fetus. Rituximab-based chemotherapy (R-CHOP) is now considered the standard of care and generally considered safe for the treatment of aggressive lymphomas during pregnancy except during the first trimester.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded106    
    Comments [Add]    

Recommend this journal